Intraocular Melanoma Completed Phase 2 Trials for GP-100 antigen (DB14800)

Also known as: Intraocular melanoma NOS

IndicationStatusPhase
DBCOND0028574 (Intraocular Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00003339Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaTreatment
NCT00031733Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaTreatment
NCT00032045Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaTreatment